Contact Us
Drug Search Results
More Filters [+]

Trotabresib

Alternative Names: trotabresib, cc-90010, cc90010, cc 90010
Latest Update: 2024-10-07
Latest Update Note: Clinical Trial Update

Product Description

Trotabresib is an orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/118021883)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trotabresib

Countries in Clinic: Canada, Japan, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: B-Cell Marginal Zone Lymphoma|Basal Cell Carcinoma|Brain Cancer|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Large Cell Carcinoma|Lymphoma|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT03936465

P1

Completed

Lymphoma|Brain Cancer

2024-03-16

JapicCTI-205272

P1

Active

Large Cell Carcinoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma|Basal Cell Carcinoma

2022-12-31

Recent News Events

Date

Type

Title

10/12/2023

News Article

 Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

06/02/2023

PubMed

 Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.

05/01/2023

PubMed

 BRD4: New hope in the battle against glioblastoma.

03/13/2023

PubMed

 BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.

09/08/2020

News Article

 Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions